Pearl Polymers (PEARLPOLY)

Asset Play

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Current Price₹16.77
Market Cap₹28.23 Cr
P/E Ratio0
ROCE-15.93%
ROE-15.32%
Dividend Yield0%
Profit Growth26.13%
Debt/Equity
Sales Growth-10.2%
Promoter Holding55.58%
52-Week Range₹12.75 — ₹33.28
SectorConsumer Durables
Book Value₹17.19

Strengths

Concerns

AI Analysis

At ₹21, Pearl Polymers looks like a classic Graham-style bargain on the surface: I pay 87 paise for every rupee of book value, with book value at ₹24.08. But cheap can be a value trap when the business burns capital. The numbers tell me this is not a wonderful company. Return on equity is -12.76%, and return on capital employed is -15.93%. Sales have shrunk 14.39%, and the latest quarter does only ₹5 crore of revenue while losing ₹2 crore. There is no dividend, and the P/E is meaningless because earnings are negative. The reported 26.13% profit growth is likely just a smaller loss; Graham would call that arithmetic, not economics. The balance sheet support is the main attraction. At a market cap of ₹32 crore, the stock is priced below tangible assets. Promoter holding of 55.58% is encouraging; owners have substantial skin in the game. A Piotroski score of 5/9 is moderate, not enough to signal quality. However, my job is to buy assets in relation to earnings power. If this company keeps losing ₹2 crore per quarter, the book value of ₹24.08 will melt away, and today's 13% discount will become a full premium to a diminished asset. I cannot call this a growing business; it is a shrinking one. The moat in consumer plastics is weak. I would need evidence of sales stabilisation, cost discipline, and a credible path to positive return on capital. For now, Pearl Polymers is an asset play for special-situation investors, not a compounding machine. I'd keep it on a watch list and demand a wider margin of safety or visible turnaround before committing.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer